US3574821A - Feminine hygiene spray deodorant compositions - Google Patents

Feminine hygiene spray deodorant compositions Download PDF

Info

Publication number
US3574821A
US3574821A US677018A US3574821DA US3574821A US 3574821 A US3574821 A US 3574821A US 677018 A US677018 A US 677018A US 3574821D A US3574821D A US 3574821DA US 3574821 A US3574821 A US 3574821A
Authority
US
United States
Prior art keywords
propellant
weight
bactericide
composition
emollient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US677018A
Inventor
Rolf Wilhelm Pfirrmann
Peter Geistlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mediline AG
Original Assignee
Mediline AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediline AG filed Critical Mediline AG
Application granted granted Critical
Publication of US3574821A publication Critical patent/US3574821A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00Anti-perspirants or body deodorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43Guanidines
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00Materials not provided for elsewhere
    • C09K3/30Materials not provided for elsewhere for aerosols

Definitions

  • An article of toiletry in the form of an aerosol spray unit for use in feminine hygiene is prepared by filling a suitable aerosol container with a composition including an organic aerosol propellant substantially at least as volatile as dichlorodifluoromethane, from 0.01%-10% by weight of at least one cosmetically acceptable bactericide and from 0.01%10% by weight of at least one emollient substance which may be a fat, oil or oily or fatty nonionic emulsifying agent, the composition containing less than 10% by weight of undissolved solid material.
  • a particularly convenient method of reducing the above-described body odor is to spray an antibacterial composition, formulated in an organic aerosol propellant, onto the area concerned, particularly the external vaginal area, whereby unwanted bacterial activity is reduced or prevented.
  • Spraying is especially effective since it facilitates direct application of the bactericidal substances without the use of toilet tissues and the like and enables any particular area to be readily treated Without substantial irritation of the skin or mucous membrane.
  • a spray container is easily carried, for example, in a hand-bag, and does not have to be frequently replaced as is the case with medicated toilet tissues etc.
  • the propellant employed should be as highly volatile as possible to reduce the quantity of unevaporated spray reaching the skin. dichlorodifluoromethane being especially suitable in this respect.
  • the propellant used should be substantially at least 3,574,821 Patented Apr. 13, 1971 as volatile as dichlorodifiuoromethane and by this means the propellant completely or nearly completely evaporates before the composition contacts the target area.
  • the composition must be dry and contain no water or other material such that the product when used would leave Wet and/or messy deposits which would soil the clothing.
  • the product should have no astringent or irritant properties as are caused by astringents customarily used in deodorant preparations.
  • substantial amounts of ethanol, also customarily used in cosmetic spray formulations, must be avoided, although minor amounts may be present to promote solubility of the bactericide in the liquified propellant.
  • the antibacterial substance or substances used as active material in the compositions should, of course, be substantially non-irritant to the skin and mucous membrane.
  • an organic aerosol propellant even one which is highly volatile, small quantities of the liquid propellant may be deposited on the skin and mucous membrane and cause irritation.
  • emollient substances may be oils or fats or may be non-toxic oily or fatty emulsifying agents.
  • the emollient effect is accompanied by improved dispersion of the bactericide in the propellant and it has also been found that the emollient helps in holding the bactericide in place, and hence prolongs its duration of action.
  • Products based upon dichlorodifluoromethane without an emollient have been found to have a comparatively short duration of action, a problem which was not encountered when prior customarily used propellants were present.
  • fat and oil we mean substances exerting an emollient action upon human skin and mucous membrane and being of a fatty or oily physical character.
  • the terms thus include not only triglycerides but also substances such as long chain fatty alcohols and long chain fatty acid esters having similar physical and emollient properties to the natural fats and oils.
  • Essential oils such as perfume oils, cannot be classed as emollient substances and are not included within the term oil as used herein, it being understood that perfume oils may additionally be included in the compositions according to the invention purely for their odoriferous properties.
  • Fluoro-aliphatic hydrocarbons are especially suitable propellants, but, as indicated, the propellant should have a volatility substantially at least that of dichloro-difluoromethane which has a vapor pressure of five atmospheres (absolute) at 16.l 0, this being necessary in order to insure that little, if any, liquid propellant reaches the skin to cause burning upon application of the composition.
  • the required volatility can be assured by selecting a single propellant having the requisite low boiling point, or by a suitable mixture of propellants, one of which can have a relatively high boiling point.
  • Fluoro-hydrocarbon derivatives are preferred, for example, trichlorofluoromethane, dichloromonofluoromethane, dichlorodifiuoromethane, difluoromonochloromethane, monochlorotrifluoromethane, dichlorotetrafluoroethane, difluoroethane, monochlorodifluoroethane, monofluorodichloroethane, or octafiuorocyclo butane, it being understood that the fluoro-hydrocarbons of relatively high boiling point will be used only in admixture with at least one propellant of high volatility. Lower paratfins such as propane and butane are also useful propellants, particularly when employed in admixture with the preferred propellants of the invention. In general,
  • the propellant should be sufiiciently volatile to reduce to a minimum the quantity of liquid spray reaching the skin, dichlorodifluoromethane, of itself, being especially suitable in this respect.
  • the bactericidal substance must be one acceptable for use in a cosmetic or toilet preparation as distinct to sub stances which are prescription items or in any other way unsuitable for a purely cosmetic preparation.
  • the bactericide must further be compatible with the skin and mucous membrane.
  • halogenophenyl bactericides such as 2,4-dichloro-3,S-xylenol, 3,4, 6-trichlorophenol, 4-chloro-3,5-xylenol, tribromo-salicylanilide 4-chloro-2-cyclopentylphenol, 2-hydroxy-2',4,4'- trichlorodiphenyloxide, 2,2 dihydroxy 3,3',5,5'-tetrachlorodiphenylsulfide, 2,2 thiobis (4-bromophenol), 2,2 thiobis-(4,6 dichlorophenol), chlorophenylglycerly ethers and 3,5-dibromo-3'-trifluoromethylsalicylanilide and the especially preferred bactericides bis-p chlorophenyl-diguanidinohexane and its acid addition salts, such as the diacetate, dichloride and digluconate, and 2,2'-methylene-bis-(
  • bactericides include long-chain quaternary ammonium compounds, such as cetyl-trimethyl-ammonium bromide, lauryl isoquinolinium bromide and saccharinates of quaternaries, nitrofuran derivatives, such as N-(S- nito-2-furfurylidene)-1-an1inohydantoin and N-(S-nitro-Z- furfurylidene)-3-amino-2-oxazolidone etc.
  • bactericidal urea-formaldehyde condensation products as described for example in US. Pat. No.
  • hydroxymethylene derivatives of thiourea such as N-hydroxymethyl-N- methyl-thiourea, trichlorocarbanilide, trishydroxymethyl, nitromethoxy (3 chlorallyl) 3,5,7-t1'iaza 1 azonioadamantane chloride, salts of 1-hydroxy-pyridine-2-thione, tetramethyl thiuram disulfide, N-trichloromethylthio-l' cyclohexane 1,2 dicarboximide, 1,6 bis(4-ethylmercaptophenylbiguanide)-hexane and its salts, amyl-meta cresol, alkyl parahydroxybenzoates and 3-trifluoromethyl- 4,4-dichlorocarbanilide.
  • thiourea such as N-hydroxymethyl-N- methyl-thiourea, trichlorocarbanilide, trishydroxymethyl, nitromethoxy (3 chlorallyl) 3,5,7-t1
  • the bactericidal spectrum of the material is advantageous for the bactericidal spectrum of the material to be broad and to include activity against both Gram-positive and Gram-negative bacteria. It is often desirable, therefore to use two or more bactericidal compounds to ensure a broad range of activity. It is especially useful to combine the halogeno-phenyl bactericides with the long-chain quaternary ammonium compounds since the latter also possess a useful cleansing action in assisting removal of undesirable malodorous substances, flakes of skin etc. from the surface.
  • the halogeno-phenyl bactericide preferably predominates in such compositions and one useful combination is hexachlorophene, i.e. 2,2-methylene bis-(3,4,6-trichlorophenol) or bis-p-chlorophenyl-diguanidino hexane with a quaternary ammonium compound, such as cetyltrimethyl ammonium bromide, with the ratio of halogenophenyl bactericide to quaternary ammonium compound being about 10:1 by weight.
  • hexachlorophene i.e. 2,2-methylene bis-(3,4,6-trichlorophenol) or bis-p-chlorophenyl-diguanidino hexane
  • a quaternary ammonium compound such as cetyltrimethyl ammonium bromide
  • nonionic emulsifying agents include sorbitan mono-fatty acid esters and their polyoxyethylene derivatives, such as sorbitan mono-oleate, mono-laureate or mono-stearate and their polyoxyethylene derivatives, oxyethylated long chain alcohols, ethers thereof and esters thereof, such as oxyethylated lanolin, oxyethylated oleyl alcohol and ethers of such alcohols, oxyethylated phosphoric acid esters of long chain fatty alcohols, such as oleyl, lauryl or woolfat alcohol e.g.
  • One class of compounds especially suitable as emollient substance and also well suited to assist solution or suspension of halogeno-phenyl bactericides is the saturated and unsaturated long chain alcohols, such as cetyl alcohol, lauryl alcohol, myristyl alcohol, stearyl alcohol, oleyl alcohol, oleylcetyl alcohol and octyldodecanol.
  • Emollients derived from such alcohols can also be used, for example ethers thereof, as well as esters of higher fatty acids, such as adipic acid, caproic capric and caprylic acids, stearic acid, myristic acid, palmitic, linoleic or linolenic acid, e.g., the ethyl, isopropyl, glyceryl, polyoxyethylated glyceryl, or polyglycol esters.
  • One particularly useful fat is hydrogenated and refined fat from animal skins; this fat is relatively hard and such hard fats are preferably used in combination with a softer fat or oil, e.g. purceline oil or isopropylmyristate.
  • non-ionic emulsifying agents especially when used in combination with oils such as isopropyl myristate or purceline oil, are polyethylene glycol stearate and oxyethylated orthophosphoric acid esters of long chain alcohols. All of the above substances not only aid solution or suspension of the active bactericide but also exert an emollient or soothing effect and, furthermore, assist retention of the bactericide on the surface.
  • the concentration of the bactericidal material in the spray liquid is as stated above between 0.01% by Weight and 10% by weight depending on the type of liquid carrier used and the activity of the bactericide. Concentrations of the bactericide in the liquefied propellant of between 0.05% and 2.0%, e.g. about 0.1% by weight, are especially convenient, having regard to bactericidal activity.
  • the concentration of surface active material or emollient is preferably of approximately the same order as the active bactericide, namely between 0.01% and 10% by weight, but the concentration of such material is most preferably about twice to four times, that of the bactericide, i.e. preferably 0.1% to 8.0%.
  • the material may be formulated as a suspension in the propellant, e.g. by grinding to a very fine powder, for example, of a particle size below 101w.
  • Such a suspension can be sprayed from an aerosol container without requiring a surface active agent to maintain the material in suspension. It will be apparent from the above, however, that there should be less than about 10% by weight of undissolved solid material in the pack aged composition.
  • a lower aliphatic alcohol such as ethanol or isopropanol, may advantageously be present in the compositions.
  • lower alcohols reduce the rate of evaporation of the propellant and reduce the tendency ofthe dissolved components to precipitate at the low temperatures generated by rapid evaporation.
  • concentration of lower alcohol in the compositions is preferably between 0.2% and 2.0% by weight.
  • no more than minor amounts of lower alcohols, such as ethanol, can be present, since excessive quantities will no longer fulfill the requirement that the composition must be nonirritant to the skin and mucous membrane.
  • aerosol spray units containing a composition according to the invention.
  • Such spray units will be provided with a nozzle having a valve to allow ejection of spray liquid to take place only when the valve is opened by the user and a dip tube leading from the nozzle to the bottom of the vessel to carry liquid under pressure up to the nozzle.
  • the body of the aerosol container is preferably cylindrical and the walls and bottom advantageously consti tute a single sheet of metal or plastic to avoid joints which would weaken the construction. Where metal is used, the
  • the inner side is preferably treated to avoid corrosion, e.g. by varnishing.
  • f 1 l The nozzle aperture is preferably below 0.8 mm. to ensure a fine uniform spray and in the case ofthe more volatile propellants, where the spray velocity would normally be very high and; the spray thus reach the skin in liquid form before evaporation could take place. it is preferred to use a nozzle adapted to reduce the spray velocity.
  • EXAMPLE 1 0.1 g. cetyl-trimethylammonium bromide 0.4 g. polyoxyethylene-sorbitan monolaurate 0.2 g. ethanol a 0.1 g. perfume oil are stirred together and added to 70 g. dichlorodifiuormethane in an aerosol container.
  • EXAMPLE 4 0.1 g. 2,2-methylene-bis(3,4,6-trichlorophenol) 0.3 g. oxyethylated oleyl alcohol 0.2 g. oxyethylated orthophosphoric acid ester Of oleyl alcohol (C18H35O 8P0 0.2 g. perfume oil are stirred together and added to 70 g. difluorodichloromethane in an aerasol container.
  • EXAMPLE 5 0.07 g. bis-p-chlorophenyl diguanidohexane acetate 0.07 g. perfume 0.1 g. cetyl alcohol and 0.06 g. octyldodecanol are stirred together and added to 70 g. difluorodichloromethane in an aerosol container.
  • the difluorodichloromethane may be replaced by other fluoro-chloro methane or ethane propellants alone or in admixture provided that the total propellant is substantially at least as volatile as dichlorodifluoromethane.
  • EXAMPLE 6 0.07 g. 2,2-methylene-bis-(3,4,6-trichlorophenol) were dissolved in 1.00 g. ethanol (96% by volume) and lightly warmed with 0.5 g. isopropyl myristate (pure) and 0.07 g. perfume oil to give an oily liquid. The liquid was then filledinto a 2.5 ounce aerosol container by the conventional vacuumcrimping method with the valve closed and the container filled with difiuorodichloromethane to make up to 70 g.
  • EXAMPLE 7 EXAMPLE 8 0.07 g. Bis(p-chlorophenyldiguanidohexane acetate) 1.00 g. isopropanol 0.5 g. isopropyl myristate 0.2 g. hydrogenated hide fat and 0.07 g. perfume oil are mixed and difiuorodichloromethane added in an aerosol container up to a total of 70 g.
  • EXAMPLE 9 70 mg. bis-(p-chlorophenyldiguanidohexane) diacetate (particle size under 1 mp) 300 mg. sesame oil 70 mg. perfume oil were stirred together and added to 70 g. difluorodichloromethane in an aerosol container.
  • EXAMPLE 10 70 g. dichlorodifluorotmethane 100 mg. hexachlorophene '2 g. hexyl laurate 0.1 g. perfume oil If desired this formulation may also contain 0.2 g. of ethanol.
  • EXAMPLE 11 2 g. of hexyl laurate, 0.1 g. of perfume oil, 100 mg. of hexachlorophene were mixed together and incorporated with 70 g. of a propellant mixture consisting of dichlorodifluoromethane and 20% of tetrafluorodichloroethane.
  • the propellant in this example consists of a mixture of dichlorodifluoromethane:butane in the proportion of 80% to 20% by weight.
  • EXAMPLE 14' 70 mg. hexachlorophene 70 mg. perfume oil 700 mg. emollient 35 mg.
  • the emollient component has the followmg composition:
  • the propellant is a mixture of dichlorodifluoromethane and monofluorotrichloromethane in the ratio by weight of 90: 10.
  • a non-irritant anhydrous aerosol spray composition in an aerosol container for use on the female external vaginal area consisting essentially of an organic aerosol propellant having a vapor pressure of at least the order of five atmospheres at 161 C., from 0.0l%% by weight of a cosmetic bactericide substantially non-irritant to the skin and mucous membrane and active against odor-producing bacteria infesting said vaginal area, and from 0.01%10% by weight of an emollient substance of a fatty or oily physical character soothing the skin and mucous membrane and counteracting irritation of said vaginal area and containing less than 10% by weight of undissolved solid material.
  • composition as claimed in claim 1 in which there is present an amount of said emollient substance from two to four times the amount of said bactericide.
  • composition as claimed in claim 1 in which the concentration of said bactericide in said propellant is within the range of about 0.05% to 2.0% by weight and the concentration of said emollient substance in said propellant is within the range of 0.1% to 8.0% by weight.
  • said propellant is dichlorodifluoromethane and said bactericide is 2,2 methylenebis (3,4,6 trichlorophenol, bis p a chlorophenyldiquanidohexane or its acid addition salts, or cetyl-trimethylammonium bromide.
  • said bactericide is 2,2-methylene-bis-(3,4,6-trichlorophenol).
  • composition as claimed in claim 4 in which said bactericide is bis-p-chlorophenyldiguanidohexane or its acid addition salts.
  • composition as claimed in claim 4 in which said bactericide is cetyl-trimethylammonium bromide.
  • composition as claimed in claim 3 in which said emollient substance is cetyl, lauryl, mristyl, stearyl, oleyl, oleylcetyl or octyldodecyl alcohol.
  • composition as claimed in claim 3 in which said emollient substance is a mixture of isopropyl myristate and hydrogenated hide fat.
  • composition as claimed in claim 3 containing from about 0.2% to about 2.0 by weight of an alcohol selected from the group consisting of ethanol and isopropanol.
  • anilide 4-chloro-2-cycl0pentylphenol should read anilide, 4-c hloro2-cyclopentylphenol,;
  • caproic capric should read caproic, capric.

Abstract

AN ARTICLE OF TIOLETRY IN THE FORM OF AN AEROSOL SPRAY UNIT FOR USE IN FEMININE HYGIENE IS PREPARED BY FILLING A SUITABLE AEROSOL CONTAINER WITH A COMPOSITION INCLUDING AN ORGANIC AEROSOL PROPELLANT SUBSTANTIALLY AT LEATST AS VOLATILE AS DICHLORODIFLUOROMETHANE, FROM 0.01%-10% BY WEIGHT OF AT LEAST ONE COSMETICALLY ACCEPTABLE BACTERICIDE AND FROM 0.01%-10% BY WEIGHT OF AT LEAST ONE EMOLLIENT SUBSTANCE WHICH MAY BE A FAT, OIL OR OILY OR FATTY NONIONIC EMULSIFYING AGENT, THE COMPOSITION CONTAINING LESS THAN 10% BY WEIGHT OF UNDISSOLVED SOLID MATERIAL.

Description

United States Patent Ofice 3,574,821 FEMININE HYGIENE SPRAY DEODORANT COMPOSITIONS Rolf Wilhelm Pfirrmann and Peter Geistlich, Lucerne, Switzerland, assignors to Mediline A.G., Wolhusen, Lucerne, Switzerland No Drawing. Continnation-in-part of application Ser. No. 370,111, May 25, 1964. This application Oct. 23, 1967, Ser. No. 677,018 Claims priority, application Great Britain, May 31, 1963, 21,976/ 63 Int. Cl. A61k 9/00; A61l 23/00 US. Cl. 424-45 10 Claims ABSTRACT OF THE DISCLOSURE An article of toiletry in the form of an aerosol spray unit for use in feminine hygiene is prepared by filling a suitable aerosol container with a composition including an organic aerosol propellant substantially at least as volatile as dichlorodifluoromethane, from 0.01%-10% by weight of at least one cosmetically acceptable bactericide and from 0.01%10% by weight of at least one emollient substance which may be a fat, oil or oily or fatty nonionic emulsifying agent, the composition containing less than 10% by weight of undissolved solid material.
This application is a continuation-in-part of copending US. application Ser. No. 370,111, filed May 25, 1964, now abandoned.
It is often difiicult for females to maintain a high order of personal cleanliness after urination and other elimination, particularly where facilities are not available for washing the lower pelvic region. Toilet tissue is often irritant to the skin and mucous membrane of this region and ineffective in complete removal of metabolic prod ucts. The resulting undesirable body odor has been recognized by us to be caused by the presence of microorganisms which by breaking down these unremoved metabolic products, liberate malodorous substances.
It is thus the object of the present invention to provide a toilet or cosmetic preparation which can be quickly and conveniently employed to overcome the above difficulties.
We have found that a particularly convenient method of reducing the above-described body odor is to spray an antibacterial composition, formulated in an organic aerosol propellant, onto the area concerned, particularly the external vaginal area, whereby unwanted bacterial activity is reduced or prevented. Spraying is especially effective since it facilitates direct application of the bactericidal substances without the use of toilet tissues and the like and enables any particular area to be readily treated Without substantial irritation of the skin or mucous membrane. Further, a spray container is easily carried, for example, in a hand-bag, and does not have to be frequently replaced as is the case with medicated toilet tissues etc.
However, because of the particularly sensitive nature of the mucous membrane present in the area being treated, We encountered difficult problems which had to be solved before there could be formulated an effective composition which was at the same time highly acceptable to the user. In particular, as distinct from the aerosol spray formulations conventionally employed to apply deodorants, antiperspirants and cosmetics to less sensitive areas of the body, the propellant employed should be as highly volatile as possible to reduce the quantity of unevaporated spray reaching the skin. dichlorodifluoromethane being especially suitable in this respect. Thus in other words, the propellant used should be substantially at least 3,574,821 Patented Apr. 13, 1971 as volatile as dichlorodifiuoromethane and by this means the propellant completely or nearly completely evaporates before the composition contacts the target area. Otherwise, a pronounced so-called burning or chilling sensation results which causes discomfort to the user and discourages use of the preparation. Also, the composition must be dry and contain no water or other material such that the product when used would leave Wet and/or messy deposits which would soil the clothing. Moreover, the product should have no astringent or irritant properties as are caused by astringents customarily used in deodorant preparations. For similar reasons substantial amounts of ethanol, also customarily used in cosmetic spray formulations, must be avoided, although minor amounts may be present to promote solubility of the bactericide in the liquified propellant.
The antibacterial substance or substances used as active material in the compositions should, of course, be substantially non-irritant to the skin and mucous membrane. In spraying with an organic aerosol propellant, even one which is highly volatile, small quantities of the liquid propellant may be deposited on the skin and mucous membrane and cause irritation. We have found that such irritation can be reduced or avoided completely by including in the aerosol composition one or more emollient substances. Such emollient substances may be oils or fats or may be non-toxic oily or fatty emulsifying agents. In the case of the emulsifying agents, the emollient effect is accompanied by improved dispersion of the bactericide in the propellant and it has also been found that the emollient helps in holding the bactericide in place, and hence prolongs its duration of action. Products based upon dichlorodifluoromethane without an emollient have been found to have a comparatively short duration of action, a problem which was not encountered when prior customarily used propellants were present.
By the terms fat and oil as used herein, we mean substances exerting an emollient action upon human skin and mucous membrane and being of a fatty or oily physical character. The terms thus include not only triglycerides but also substances such as long chain fatty alcohols and long chain fatty acid esters having similar physical and emollient properties to the natural fats and oils. Essential oils, however, such as perfume oils, cannot be classed as emollient substances and are not included within the term oil as used herein, it being understood that perfume oils may additionally be included in the compositions according to the invention purely for their odoriferous properties.
Fluoro-aliphatic hydrocarbons are especially suitable propellants, but, as indicated, the propellant should have a volatility substantially at least that of dichloro-difluoromethane which has a vapor pressure of five atmospheres (absolute) at 16.l 0, this being necessary in order to insure that little, if any, liquid propellant reaches the skin to cause burning upon application of the composition. The required volatility can be assured by selecting a single propellant having the requisite low boiling point, or by a suitable mixture of propellants, one of which can have a relatively high boiling point. Fluoro-hydrocarbon derivatives are preferred, for example, trichlorofluoromethane, dichloromonofluoromethane, dichlorodifiuoromethane, difluoromonochloromethane, monochlorotrifluoromethane, dichlorotetrafluoroethane, difluoroethane, monochlorodifluoroethane, monofluorodichloroethane, or octafiuorocyclo butane, it being understood that the fluoro-hydrocarbons of relatively high boiling point will be used only in admixture with at least one propellant of high volatility. Lower paratfins such as propane and butane are also useful propellants, particularly when employed in admixture with the preferred propellants of the invention. In general,
as stated, the propellant should be sufiiciently volatile to reduce to a minimum the quantity of liquid spray reaching the skin, dichlorodifluoromethane, of itself, being especially suitable in this respect.
The bactericidal substance must be one acceptable for use in a cosmetic or toilet preparation as distinct to sub stances which are prescription items or in any other way unsuitable for a purely cosmetic preparation. The bactericide must further be compatible with the skin and mucous membrane. Examples of these include certain halogenophenyl bactericides, such as 2,4-dichloro-3,S-xylenol, 3,4, 6-trichlorophenol, 4-chloro-3,5-xylenol, tribromo-salicylanilide 4-chloro-2-cyclopentylphenol, 2-hydroxy-2',4,4'- trichlorodiphenyloxide, 2,2 dihydroxy 3,3',5,5'-tetrachlorodiphenylsulfide, 2,2 thiobis (4-bromophenol), 2,2 thiobis-(4,6 dichlorophenol), chlorophenylglycerly ethers and 3,5-dibromo-3'-trifluoromethylsalicylanilide and the especially preferred bactericides bis-p chlorophenyl-diguanidinohexane and its acid addition salts, such as the diacetate, dichloride and digluconate, and 2,2'-methylene-bis-(3,4,6-trichlorophenol). Other useful bactericides include long-chain quaternary ammonium compounds, such as cetyl-trimethyl-ammonium bromide, lauryl isoquinolinium bromide and saccharinates of quaternaries, nitrofuran derivatives, such as N-(S- nito-2-furfurylidene)-1-an1inohydantoin and N-(S-nitro-Z- furfurylidene)-3-amino-2-oxazolidone etc. bactericidal urea-formaldehyde condensation products (as described for example in US. Pat. No. 3,102,108) hydroxymethylene derivatives of thiourea, such as N-hydroxymethyl-N- methyl-thiourea, trichlorocarbanilide, trishydroxymethyl, nitromethoxy (3 chlorallyl) 3,5,7-t1'iaza 1 azonioadamantane chloride, salts of 1-hydroxy-pyridine-2-thione, tetramethyl thiuram disulfide, N-trichloromethylthio-l' cyclohexane 1,2 dicarboximide, 1,6 bis(4-ethylmercaptophenylbiguanide)-hexane and its salts, amyl-meta cresol, alkyl parahydroxybenzoates and 3-trifluoromethyl- 4,4-dichlorocarbanilide.
It is advantageous for the bactericidal spectrum of the material to be broad and to include activity against both Gram-positive and Gram-negative bacteria. It is often desirable, therefore to use two or more bactericidal compounds to ensure a broad range of activity. It is especially useful to combine the halogeno-phenyl bactericides with the long-chain quaternary ammonium compounds since the latter also possess a useful cleansing action in assisting removal of undesirable malodorous substances, flakes of skin etc. from the surface.
The halogeno-phenyl bactericide preferably predominates in such compositions and one useful combination is hexachlorophene, i.e. 2,2-methylene bis-(3,4,6-trichlorophenol) or bis-p-chlorophenyl-diguanidino hexane with a quaternary ammonium compound, such as cetyltrimethyl ammonium bromide, with the ratio of halogenophenyl bactericide to quaternary ammonium compound being about 10:1 by weight.
The choice of the emollient substance which may be used in the compositions will depend on the bactericidal substance and on the carrier liquid. Examples of nonionic emulsifying agents include sorbitan mono-fatty acid esters and their polyoxyethylene derivatives, such as sorbitan mono-oleate, mono-laureate or mono-stearate and their polyoxyethylene derivatives, oxyethylated long chain alcohols, ethers thereof and esters thereof, such as oxyethylated lanolin, oxyethylated oleyl alcohol and ethers of such alcohols, oxyethylated phosphoric acid esters of long chain fatty alcohols, such as oleyl, lauryl or woolfat alcohol e.g. the substance sold under the name Hostaphat KO 280 by Farbwerke Hoechst A.G.; monoand di-ethanolamides of long chain fatty acids such as coco acid poly-diethanolamide, stearic acid mono-ethanolamide, myristic acid mono-ethanolamide etc.
One class of compounds especially suitable as emollient substance and also well suited to assist solution or suspension of halogeno-phenyl bactericides is the saturated and unsaturated long chain alcohols, such as cetyl alcohol, lauryl alcohol, myristyl alcohol, stearyl alcohol, oleyl alcohol, oleylcetyl alcohol and octyldodecanol. Emollients derived from such alcohols can also be used, for example ethers thereof, as well as esters of higher fatty acids, such as adipic acid, caproic capric and caprylic acids, stearic acid, myristic acid, palmitic, linoleic or linolenic acid, e.g., the ethyl, isopropyl, glyceryl, polyoxyethylated glyceryl, or polyglycol esters. for example, isopropyl myristate, isopropylpalmitate, purceline oil, sesame oil, almond oil and polyethylene glycol stearate (e.g. the substances sold under the name Chremophor A by Badische Anilin und Soda-fabrik). One particularly useful fat is hydrogenated and refined fat from animal skins; this fat is relatively hard and such hard fats are preferably used in combination with a softer fat or oil, e.g. purceline oil or isopropylmyristate.
It is especially preferred to use an oil or fat in combination with a non-ionic emulsifying agent. For such combinations, preferred non-ionic emulsifying agents, especially when used in combination with oils such as isopropyl myristate or purceline oil, are polyethylene glycol stearate and oxyethylated orthophosphoric acid esters of long chain alcohols. All of the above substances not only aid solution or suspension of the active bactericide but also exert an emollient or soothing effect and, furthermore, assist retention of the bactericide on the surface.
The concentration of the bactericidal material in the spray liquid is as stated above between 0.01% by Weight and 10% by weight depending on the type of liquid carrier used and the activity of the bactericide. Concentrations of the bactericide in the liquefied propellant of between 0.05% and 2.0%, e.g. about 0.1% by weight, are especially convenient, having regard to bactericidal activity. The concentration of surface active material or emollient is preferably of approximately the same order as the active bactericide, namely between 0.01% and 10% by weight, but the concentration of such material is most preferably about twice to four times, that of the bactericide, i.e. preferably 0.1% to 8.0%.
Where the bactericidal substance is insoluble in the aerosol propellant, the material may be formulated as a suspension in the propellant, e.g. by grinding to a very fine powder, for example, of a particle size below 101w.
Such a suspension can be sprayed from an aerosol container without requiring a surface active agent to maintain the material in suspension. It will be apparent from the above, however, that there should be less than about 10% by weight of undissolved solid material in the pack aged composition.
A lower aliphatic alcohol, such as ethanol or isopropanol, may advantageously be present in the compositions. In general, lower alcohols reduce the rate of evaporation of the propellant and reduce the tendency ofthe dissolved components to precipitate at the low temperatures generated by rapid evaporation. The concentration of lower alcohol in the compositions is preferably between 0.2% and 2.0% by weight. As pointed out earlier, no more than minor amounts of lower alcohols, such as ethanol, can be present, since excessive quantities will no longer fulfill the requirement that the composition must be nonirritant to the skin and mucous membrane.
According to the invention we also provide aerosol spray units containing a composition according to the invention. Such spray units will be provided with a nozzle having a valve to allow ejection of spray liquid to take place only when the valve is opened by the user and a dip tube leading from the nozzle to the bottom of the vessel to carry liquid under pressure up to the nozzle.
The body of the aerosol container is preferably cylindrical and the walls and bottom advantageously consti tute a single sheet of metal or plastic to avoid joints which would weaken the construction. Where metal is used, the
inner side is preferably treated to avoid corrosion, e.g. by varnishing. f 1 l The nozzle aperture is preferably below 0.8 mm. to ensure a fine uniform spray and in the case ofthe more volatile propellants, where the spray velocity would normally be very high and; the spray thus reach the skin in liquid form before evaporation could take place. it is preferred to use a nozzle adapted to reduce the spray velocity.
In order that the invention may be well understood we give the following examples by way of illustration only. The perfume on used in theseexamples was a mixture of Eroica 3739/2 sold by Dragoco of Holzminden, Germany and IFF 1 239, sold by International Flavors and Fragrances, Holland:
EXAMPLE 1 0.1 g. cetyl-trimethylammonium bromide 0.4 g. polyoxyethylene-sorbitan monolaurate 0.2 g. ethanol a 0.1 g. perfume oil are stirred together and added to 70 g. dichlorodifiuormethane in an aerosol container.
EXAMPLE 2 EXAMPLE, 3
0.1 2,2-methylene-bis- 3,4,6-trichlorophenol) 0.5% isopropyl myristate 0.1% perfumeoil and 2.0% ethanol (96% of volume)v are mixed together and added to 20.0% propane-butane and 77.3 difluorodichloromethane in an aerosol container. 1
EXAMPLE 4 0.1 g. 2,2-methylene-bis(3,4,6-trichlorophenol) 0.3 g. oxyethylated oleyl alcohol 0.2 g. oxyethylated orthophosphoric acid ester Of oleyl alcohol (C18H35O 8P0 0.2 g. perfume oil are stirred together and added to 70 g. difluorodichloromethane in an aerasol container.
EXAMPLE 5 0.07 g. bis-p-chlorophenyl diguanidohexane acetate 0.07 g. perfume 0.1 g. cetyl alcohol and 0.06 g. octyldodecanol are stirred together and added to 70 g. difluorodichloromethane in an aerosol container.
If desired, the difluorodichloromethane may be replaced by other fluoro-chloro methane or ethane propellants alone or in admixture provided that the total propellant is substantially at least as volatile as dichlorodifluoromethane.
EXAMPLE 6 0.07 g. 2,2-methylene-bis-(3,4,6-trichlorophenol) were dissolved in 1.00 g. ethanol (96% by volume) and lightly warmed with 0.5 g. isopropyl myristate (pure) and 0.07 g. perfume oil to give an oily liquid. The liquid was then filledinto a 2.5 ounce aerosol container by the conventional vacuumcrimping method with the valve closed and the container filled with difiuorodichloromethane to make up to 70 g.
EXAMPLE 7 EXAMPLE 8 0.07 g. Bis(p-chlorophenyldiguanidohexane acetate) 1.00 g. isopropanol 0.5 g. isopropyl myristate 0.2 g. hydrogenated hide fat and 0.07 g. perfume oil are mixed and difiuorodichloromethane added in an aerosol container up to a total of 70 g.
EXAMPLE 9 70 mg. bis-(p-chlorophenyldiguanidohexane) diacetate (particle size under 1 mp) 300 mg. sesame oil 70 mg. perfume oil were stirred together and added to 70 g. difluorodichloromethane in an aerosol container.
EXAMPLE 10 70 g. dichlorodifluorotmethane 100 mg. hexachlorophene '2 g. hexyl laurate 0.1 g. perfume oil If desired this formulation may also contain 0.2 g. of ethanol.
EXAMPLE 11 2 g. of hexyl laurate, 0.1 g. of perfume oil, 100 mg. of hexachlorophene were mixed together and incorporated with 70 g. of a propellant mixture consisting of dichlorodifluoromethane and 20% of tetrafluorodichloroethane.
1 'EXAMPLE 12 G. Dichlorodifluoromethane 70 Bis-(p-chlorophenyldiguanidohexane)dichloride 0.07
The propellant in this example consists of a mixture of dichlorodifluoromethane:butane in the proportion of 80% to 20% by weight.
EXAMPLE 14' 70 mg. hexachlorophene 70 mg. perfume oil 700 mg. emollient 35 mg. Dow Corning fluid F-157 (Stearyl ester of dimethylpolysiloxane) 70 g. dichlorodifluoromethane In this example the emollient component has the followmg composition:
Percent by wt. Isopropyl myristate 40 Purcellin Oil (Dragoco, Holzminden, Germany) 40 Hide fat (hydrogenated) 20 In this example instead of Dow Corning fluid F-157 other Dow Corning Silicon fluids which may be used are 225 Fluid, 420 fluid and 471 fluid.
EXAMPLE 15 In this example the propellant is a mixture of dichlorodifluoromethane and monofluorotrichloromethane in the ratio by weight of 90: 10.
EXAMPLE 16 1000 mg. Polynoxylin 1000 mg. Dow Corning Medical fluid 200 70 mg. dichlorodifluoromethane 100 mg. perfume oil Polynoxylin is a bactericidal urea-formaldehyde polycondensation product marketed by Ed. Geistlich Sohne A.G. fur Chemische 'Industrie, Wolhusen, Lucerne, Switzerland.
We claim:
1. A non-irritant anhydrous aerosol spray composition in an aerosol container for use on the female external vaginal area consisting essentially of an organic aerosol propellant having a vapor pressure of at least the order of five atmospheres at 161 C., from 0.0l%% by weight of a cosmetic bactericide substantially non-irritant to the skin and mucous membrane and active against odor-producing bacteria infesting said vaginal area, and from 0.01%10% by weight of an emollient substance of a fatty or oily physical character soothing the skin and mucous membrane and counteracting irritation of said vaginal area and containing less than 10% by weight of undissolved solid material.
2. A composition as claimed in claim 1 in which there is present an amount of said emollient substance from two to four times the amount of said bactericide.
3. A composition as claimed in claim 1 in which the concentration of said bactericide in said propellant is within the range of about 0.05% to 2.0% by weight and the concentration of said emollient substance in said propellant is within the range of 0.1% to 8.0% by weight.
4. A composition as claimed in claim 3 in which said propellant is dichlorodifluoromethane and said bactericide is 2,2 methylenebis (3,4,6 trichlorophenol, bis p a chlorophenyldiquanidohexane or its acid addition salts, or cetyl-trimethylammonium bromide. I p 5. A composition as claimed in claim 4 in which said bactericide is 2,2-methylene-bis-(3,4,6-trichlorophenol).
6. A composition as claimed in claim 4 in which said bactericide is bis-p-chlorophenyldiguanidohexane or its acid addition salts.
7. A composition as claimed in claim 4 in which said bactericide is cetyl-trimethylammonium bromide.
8. A composition as claimed in claim 3 in which said emollient substance is cetyl, lauryl, mristyl, stearyl, oleyl, oleylcetyl or octyldodecyl alcohol.
9. A composition as claimed in claim 3 in which said emollient substance is a mixture of isopropyl myristate and hydrogenated hide fat.
10. A composition as claimed in claim 3 containing from about 0.2% to about 2.0 by weight of an alcohol selected from the group consisting of ethanol and isopropanol.
References Cited UNITED STATES PATENTS 2,684,924 7/1954 Rose et al. 424-326 3,227,614 1/ 1966 Schever 424-263 FOREIGN PATENTS 59,548 8/ 1947 Argentina.
. OTHER REFERENCES Merck Index, 1960, 7th Ed., P. 423, 675-67 6.
Remingtons Practice of Pharmacy, 12th 'Ed., 1961, p. 246.
Barr, M. JAPA vol. 19, No. 11, 1958, p. 675-678.
ALBERT T. MEYERS, Primary Examiner V. D. YTURNER, Assistant Examiner mg UNITED STA'IES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,574,821 Dated April 13, 1971 Inventor) Rolf Wilhelm Pfirrmann and Peter Geistlich It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 3, line 13,
"anilide 4-chloro-2-cycl0pentylphenol, should read anilide, 4-c hloro2-cyclopentylphenol,;
Column 3, line 17,
"erly" should read -eryl-,-
. Column 3, line 26,
"nito" should read --nitro-.
Column 4, line 7,
"caproic capric" should read caproic, capric.
Column 7, line 9, "70 mg. propellant" should read --70 g propellant-;
Column- 7, line 16, "70 mg. dichlorodifluoromethane"should re --70 g dichlorodifluoromethane--;
Column 7, line 35, soothing the" should read soothing to the-.
Column 8, line 6, trichlorophenol, should read -trichlorophenol) Signed and sealed this 21st day of September 1971.
ISEAL) Attest:
, EDWARD MEIETCHER, JR. ROBERT GOTTSCHALK Attesting Officer Acting Commissioner of Paton
US677018A 1963-05-31 1967-10-23 Feminine hygiene spray deodorant compositions Expired - Lifetime US3574821A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB21976/63A GB1026831A (en) 1963-05-31 1963-05-31 Preparations for use in feminine hygiene

Publications (1)

Publication Number Publication Date
US3574821A true US3574821A (en) 1971-04-13

Family

ID=10171906

Family Applications (1)

Application Number Title Priority Date Filing Date
US677018A Expired - Lifetime US3574821A (en) 1963-05-31 1967-10-23 Feminine hygiene spray deodorant compositions

Country Status (15)

Country Link
US (1) US3574821A (en)
AT (1) AT293622B (en)
BE (1) BE648529A (en)
BR (1) BR6459565D0 (en)
CH (1) CH430057A (en)
CY (1) CY583A (en)
DE (1) DE1492400A1 (en)
DK (1) DK111148B (en)
ES (1) ES299999A1 (en)
FI (1) FI47448B (en)
FR (1) FR3476M (en)
GB (1) GB1026831A (en)
MY (1) MY7100106A (en)
NL (1) NL141375B (en)
SE (1) SE300485B (en)

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929985A (en) * 1974-01-18 1975-12-30 Richardson Merrell Inc Anhydrous candicidin foam compositions
US4147769A (en) * 1976-06-28 1979-04-03 Nelson Research & Development Company Microbicidal composition
US4165375A (en) * 1975-07-09 1979-08-21 Henkel Kommanditgesellschaft Auf Aktien Low-foaming disinfecting agents based on quaternary ammonium compounds
US4632772A (en) * 1982-02-22 1986-12-30 Dexide, Inc. Mild antimicrobial detergent composition
US5780020A (en) * 1996-10-28 1998-07-14 The Proctor & Gamble Company Methods and compositions for reducing body odor
US5858335A (en) * 1997-06-09 1999-01-12 The Procter & Gamble Company Method of reducing body odor using perfume-free two phase compositions
US5861145A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method of reducing body odor using perfumed, odor absorbing, two phase compositions
US5861143A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Methods for reducing body odors and excess moisture
US5861146A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method for reducing body odor
US5861144A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Perfumed compositions for reducing body odors and excess moisture
US5871719A (en) * 1997-06-09 1999-02-16 The Procter & Gamble Company Perfume-free two phase compositions for reducing body odor
US5871718A (en) * 1997-06-09 1999-02-16 The Procter & Gamble Company Perfumed two phase compositions for reducing body odor
US5874070A (en) * 1997-06-09 1999-02-23 The Procter & Gamble Company Compositions for reducing body odor
US5874067A (en) * 1996-10-24 1999-02-23 The Procter & Gamble Company Methods for controlling environmental odors on the body
US5879666A (en) * 1996-10-24 1999-03-09 The Procter & Gamble Company Methods and compositions for reducing body odor
US5882638A (en) * 1996-10-24 1999-03-16 The Proctor & Gamble Company Methods using uncomplexed cyclodextrin solutions for controlling environmental odors
US5885599A (en) * 1996-10-28 1999-03-23 The Procter & Gamble Company Methods and compositions for reducing body odors and excess moisture
US5897854A (en) * 1997-06-09 1999-04-27 The Procter & Gamble Company Methods for reducing body odor
US5897856A (en) * 1996-10-24 1999-04-27 The Procter & Gamble Company Methods and compositions for reducing body odor
US5897855A (en) * 1996-10-24 1999-04-27 The Procter & Gamble Company Methods and compositions for reducing body odor
US5911976A (en) * 1996-10-24 1999-06-15 The Procter & Gamble Company Compositions for reducing body odor
EP1011610A1 (en) * 1997-08-15 2000-06-28 Scandinavian-American Import/Export Corporation Skin care compositions and use
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060275218A1 (en) * 2003-08-04 2006-12-07 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20090317338A1 (en) * 2003-04-28 2009-12-24 Foamix Ltd. Foamable iodine compositions
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20100150971A1 (en) * 2008-12-16 2010-06-17 Jeffery Richard Seidling Personal care composition containing a volatile and a terpene alcohol
US20110045037A1 (en) * 2007-11-30 2011-02-24 Foamix Ltd. Foam containing benzoyl peroxide
US20110178162A1 (en) * 2005-10-14 2011-07-21 Medical University Of South Carolina Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001391A (en) * 1969-04-18 1977-01-04 Plough, Inc. Means for depositing aerosol sprays in buttery form
CA937867A (en) * 1969-12-29 1973-12-04 L. Danneman Douglas Amide-stabilized dry powder aerosol antiperspirant compositions and method of preparation
US4045548A (en) * 1974-02-13 1977-08-30 The Procter & Gamble Company Aerosol antiperspirant containing emollients
US4439342A (en) * 1979-07-23 1984-03-27 United Industries Corporation Aerosol preparation
US4439343A (en) * 1979-07-23 1984-03-27 United Industries Corporation Aerosol preparation
WO1981002023A1 (en) * 1980-01-17 1981-07-23 Chemsico Inc Aerosol preparation
BR8009018A (en) * 1980-01-17 1981-11-24 Chemsico Inc DISPERSIONS IN WATER
US4439344A (en) * 1980-02-06 1984-03-27 United Industries Corporation Water dispersions
US4483783A (en) * 1982-04-15 1984-11-20 United Industries Corporation Solvent preparation
US4716032A (en) * 1983-08-03 1987-12-29 Geoffrey J. Westfall Aerosol spray composition for mastitis prevention
DE3347742A1 (en) * 1983-12-30 1985-07-11 IG Sprühtechnik GmbH, 7867 Wehr Deodorising spray

Cited By (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929985A (en) * 1974-01-18 1975-12-30 Richardson Merrell Inc Anhydrous candicidin foam compositions
US4165375A (en) * 1975-07-09 1979-08-21 Henkel Kommanditgesellschaft Auf Aktien Low-foaming disinfecting agents based on quaternary ammonium compounds
US4147769A (en) * 1976-06-28 1979-04-03 Nelson Research & Development Company Microbicidal composition
US4632772A (en) * 1982-02-22 1986-12-30 Dexide, Inc. Mild antimicrobial detergent composition
US5874067A (en) * 1996-10-24 1999-02-23 The Procter & Gamble Company Methods for controlling environmental odors on the body
US5911976A (en) * 1996-10-24 1999-06-15 The Procter & Gamble Company Compositions for reducing body odor
US5897855A (en) * 1996-10-24 1999-04-27 The Procter & Gamble Company Methods and compositions for reducing body odor
US5897856A (en) * 1996-10-24 1999-04-27 The Procter & Gamble Company Methods and compositions for reducing body odor
US5882638A (en) * 1996-10-24 1999-03-16 The Proctor & Gamble Company Methods using uncomplexed cyclodextrin solutions for controlling environmental odors
US5879666A (en) * 1996-10-24 1999-03-09 The Procter & Gamble Company Methods and compositions for reducing body odor
US5780020A (en) * 1996-10-28 1998-07-14 The Proctor & Gamble Company Methods and compositions for reducing body odor
US5885599A (en) * 1996-10-28 1999-03-23 The Procter & Gamble Company Methods and compositions for reducing body odors and excess moisture
US5858335A (en) * 1997-06-09 1999-01-12 The Procter & Gamble Company Method of reducing body odor using perfume-free two phase compositions
US5874070A (en) * 1997-06-09 1999-02-23 The Procter & Gamble Company Compositions for reducing body odor
US5871718A (en) * 1997-06-09 1999-02-16 The Procter & Gamble Company Perfumed two phase compositions for reducing body odor
US5871719A (en) * 1997-06-09 1999-02-16 The Procter & Gamble Company Perfume-free two phase compositions for reducing body odor
US5861144A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Perfumed compositions for reducing body odors and excess moisture
US5897854A (en) * 1997-06-09 1999-04-27 The Procter & Gamble Company Methods for reducing body odor
US5861146A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method for reducing body odor
US5861143A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Methods for reducing body odors and excess moisture
US5861145A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method of reducing body odor using perfumed, odor absorbing, two phase compositions
EP1011610A4 (en) * 1997-08-15 2004-08-18 Scandinavian American Imp Exp Skin care compositions and use
EP1011610A1 (en) * 1997-08-15 2000-06-28 Scandinavian-American Import/Export Corporation Skin care compositions and use
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US20090317338A1 (en) * 2003-04-28 2009-12-24 Foamix Ltd. Foamable iodine compositions
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20050031547A1 (en) * 2003-08-04 2005-02-10 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060275218A1 (en) * 2003-08-04 2006-12-07 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20110178162A1 (en) * 2005-10-14 2011-07-21 Medical University Of South Carolina Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20110045037A1 (en) * 2007-11-30 2011-02-24 Foamix Ltd. Foam containing benzoyl peroxide
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20100150971A1 (en) * 2008-12-16 2010-06-17 Jeffery Richard Seidling Personal care composition containing a volatile and a terpene alcohol
US8846063B2 (en) 2008-12-16 2014-09-30 Kimberly-Clark Worldwide, Inc. Personal care composition containing a volatile and a terpene alcohol
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Also Published As

Publication number Publication date
GB1026831A (en) 1966-04-20
DE1492400A1 (en) 1970-01-29
FR3476M (en) 1965-08-09
FI47448B (en) 1973-08-31
DK111148B (en) 1968-06-17
NL6406050A (en) 1964-12-01
ES299999A1 (en) 1964-12-16
BE648529A (en) 1964-09-16
CY583A (en) 1971-03-29
CH430057A (en) 1967-02-15
AT293622B (en) 1971-10-25
BR6459565D0 (en) 1973-09-20
MY7100106A (en) 1971-12-31
SE300485B (en) 1968-04-29
NL141375B (en) 1974-03-15

Similar Documents

Publication Publication Date Title
US3574821A (en) Feminine hygiene spray deodorant compositions
US4478853A (en) Skin conditioning composition
EP0689418B1 (en) Deodorant active-substance combinations made from wool-grease acids and partial glycerides
US6001341A (en) Deodorant and/or antiperspirant cosmetic compositions
US5690919A (en) Deodorizing cosmetic compositions
US4906454A (en) Deodorant compositions containing specific piroctone salts and perfumes
US20030215472A1 (en) Methods and compositions employing a dialkyl amide
JPH08500831A (en) Deodorant cosmetic composition having fatty acid content
EP2134319B1 (en) Compositions comprising a physiological coolant
JP3246730B2 (en) Deodorizing composition
EP1633368A2 (en) Foamable pharmaceutical compositions and methods for treating a disorder
US4110430A (en) A method of deodorizing
EP0650720A1 (en) Skin care and deodorant compositions
JPH1077222A (en) Combination of active compound having activity against bacterium, fungus and virus and based on partial glyceride and dialkyl substituted acetic acid
AU665081B2 (en) Acyl lactylates as antimicrobial actives
GB2181051A (en) Anti-acne compositions
US4263274A (en) Antiperspirant compositions and methods
WO2002013776A2 (en) Method of providing improved deodorant application to the underarm
JPH10182346A (en) Cosmetic
JPH06509112A (en) liquid deodorant composition
US20040161482A1 (en) Skin cosmetics
JPS6239698A (en) Self-purifying cleansing preparation
JPS59231013A (en) Deodorant cosmetics
US3193451A (en) Fungicidal composition of undecylenic acid derivatives
US2901399A (en) Therapeutic preparations for topical application to the skin